The Effect of Oxaliplatin Injection Combined with S-1 on Levels of CEA, CA199,TAM and the Quality of Life of Patients with Advanced Gastric Cancer
10.3969/j.issn.1003-4706.2018.01.026
- VernacularTitle:奥沙利铂针联合替吉奥胶囊治疗对晚期胃癌患者CEA、CA199、TAM水平及生活质量的影响
- Author:
Bo JIANG
1
;
Chao LIN
Author Information
1. 四川大学华西广安医院肿瘤科
- Keywords:
Oxaliplatin injection;
S-1;
Advanced;
Gastric cancer;
CEA;
CA199;
TAM;
Quality of life
- From:
Journal of Kunming Medical University
2018;39(1):113-117
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of oxaliplatin injection combined with S-1 on levels of carcinoembryonic antigen (CEA), cancer antigen 199 (CA199) and tumor associated materials (TAM) and the quality of life of patients with advanced gastric cancer. Methods The clinical data of 70 patients with advanced gastric cancer treated in our hospital from January 2013 to June 2016 were retrospectively analyzed. According to different chemotherapy regimens, the patients were divided into the study group (n=35, treated with oxaliplatin injection combined with S-1) and the control group (n=35, treated with S-1) . The short-term curative effect in the two groups was evaluated, and levels of serum tumor markers were detected before and after the treatment. The toxicity and quality of life were evaluated. Results The total effective rate of treatment and disease control rate in the study group were significantly higher than those in the control group (45.71％ and 88.57％ vs 2.86％ vs 71.43％) ( <0.05) . There were no significant differences in levels of serum CEA, CA199 and TAM between the two groups before the treatment ( >0.05) . After the treatment, levels of serum CEA, CA199 and CEA were significantly decreased ( <0.05), and the decrease was significantly greater in the study group than in the control group ( <0.05) . During and after the treatment, nausea and vomiting was more severe in the study group than in the control group ( <0.05), while the incidence rates of neutropenia, thrombocytopenia, peripheral neuritis and liver or kidney function damage showed no statistically significant difference ( > 0.05) . After the treatment, the improvement rate of KPS score in the study group was significantly higher than that in the control group (60％VS 31.42％),and the overall improvement of the quality of life was significantly better than that in the control group ( < 0.05) . Conclusion Oxaliplatin injection combined with S-1 can effectively inhibit the growth and metastasis of tumor cells, remit the condition and improve the clinical efficacy with high safety in patients with advanced gastric cancer. It also can improve the quality of life of patients.
